This was observed through an in vivo tumor model with B16F10‐OVA cells, where CD8+ T cells recognized the tumor cells with the OVA antigen and shifted the immune cell composition to increase the CD8+ T cell population and enhance the recruitment of macrophages and major histocompatibility complex (MHC) II+ dendritic cells. Here, CD8A is linked to neoplasm.